Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma
Zijian Wang, Chunyang Zhou, Yiming Zhang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 116074-116074
Open Access | Times Cited: 22

Showing 22 citing articles:

Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
Hongquan Wang, Joshua S. Fleishman, Sihang Cheng, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
The involvement of ROS-regulated programmed cell death in hepatocellular carcinoma
Hanchen Cai, Ziqi Meng, Fujun Yu
Critical Reviews in Oncology/Hematology (2024) Vol. 197, pp. 104361-104361
Closed Access | Times Cited: 13
Targeting ferroptosis: the role of non-coding RNAs in hepatocellular carcinoma progression and therapy
Weijia Wang, Behishta Hashimi, Ping Wang
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 1
Fasting enhances the efficacy of Sorafenib in breast cancer via mitophagy mediated ROS-driven p53 pathway
Ru Li, Yimei Ma, Anqi He, et al.
Free Radical Biology and Medicine (2025)
Closed Access
Identification and molecular mechanism study of a novel small molecule inhibitor targeting solute carrier family 7 member 11 for the treatment of hepatocellular carcinoma
Xiaomeng Wang, Yan Yang, Qiao Fu, et al.
New Journal of Chemistry (2025)
Closed Access
Exploring the Role of Metabolic Hyperferritinaemia (MHF) in Steatotic Liver Disease (SLD) and Hepatocellular Carcinoma (HCC)
Nikolaos-Andreas Anastasopoulos, Alexandra Barbouti, Anna Goussia, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 842-842
Open Access
Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer
Xin Wei, Weihua Cao, Shiyu Wang, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 2623-2643
Open Access
Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer
Morgann Hendrixson, Yevgeniy Gladkiy, Anita Thyagarajan, et al.
Medical Sciences (2024) Vol. 12, Iss. 2, pp. 20-20
Open Access | Times Cited: 3
Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells
Zengbin Wang, Linqing Wu, Yu Zhou, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Intracellular Magnetic Hyperthermia Sensitizes Sorafenib to Orthotopic Hepatocellular Carcinoma Via Amplified Ferroptosis
Qianqian Tang, Yanyun Wang, Bin Yan, et al.
ACS Nano (2024) Vol. 18, Iss. 43, pp. 29804-29819
Closed Access | Times Cited: 3
Mechanisms and therapeutic target of anti-tumour treatment-related Ferroptosis: How to improve cancer therapy?
Xiangyu Zhou, Lin Lin
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117323-117323
Open Access | Times Cited: 2
MCM4 potentiates evasion of hepatocellular carcinoma from sorafenib-induced ferroptosis through Nrf2 signaling pathway
Xujin Liu, Fan Zhang, Yu‐Chen Fan, et al.
International Immunopharmacology (2024) Vol. 142, pp. 113107-113107
Closed Access | Times Cited: 2
Current Treatment Methods in Hepatocellular Carcinoma
Katherine Krupa, Marta Fudalej, Anna Cencelewicz-Lesikow, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4059-4059
Open Access | Times Cited: 2
Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers
Weiqin Lu, Aihemaitijiang Aihaiti, Paziliya Abudukeranmu, et al.
Molecular and Cellular Biochemistry (2024)
Closed Access | Times Cited: 1
PART1 facilitates tumorigenesis and inhibits ferroptosis by regulating the miR-490-3p/SLC7A11 axis in hepatocellular carcinoma
Decheng Li, Meiling Wan, Xiaoling Liu, et al.
Aging (2024)
Open Access | Times Cited: 1
The Potential Role of Non-coding RNAs in Regulating Ferroptosis in Cancer: Mechanisms and Application Prospects
Ming-Yuan Cao, Zhendong Zhang, Xin-Rui Hou, et al.
Anti-Cancer Agents in Medicinal Chemistry (2024) Vol. 24, Iss. 16, pp. 1182-1196
Closed Access
Aurantio‑obtusin regulates lipogenesis and ferroptosis of liver cancer cells through inhibiting SCD1 and sensitizing RSL3
Wen Liu, Jun Deng, Xiaojun Tao, et al.
International Journal of Oncology (2024) Vol. 65, Iss. 4
Closed Access
Unveiling EFNB2 as a Key Player in Sorafenib Resistance: Insights from Bioinformatics Analysis and Functional Validation in Hepatocellular Carcinoma
Junli Pan, Quanxi Li, Junli Zhu
Biochemical Genetics (2024)
Closed Access
Echinacoside inhibits hepatocellular carcinoma progression by targeting the miR-30c-5p/FOXD1/KLF12 axis
Guoyu Wang, Yang Han, Juhua Zhuang, et al.
Technology and Health Care (2024), pp. 1-16
Closed Access
MicroRNA-mediated regulation of Ferroptosis: Implications for disease pathogenesis and therapeutic interventions
Shokufeh Razi, Javad Yaghmoorian Khojini, Hamid Norioun, et al.
Cellular Signalling (2024) Vol. 125, pp. 111503-111503
Closed Access
The Role of Fatty Acid Metabolism, the Related Potential Biomarkers, and Targeted Therapeutic Strategies in Gastrointestinal Cancers
Ruixi Xie, Ying Luo, Bowen Bao, et al.
Drug Development Research (2024) Vol. 85, Iss. 7
Closed Access
Oxygen-boosted fluorinated prodrug hybrid nanoassemblies for bidirectional amplification of breast cancer ferroptosis
Dongqi Sun, Xinxin Sun, Jianbin Shi, et al.
Journal of Controlled Release (2024) Vol. 377, pp. 619-631
Closed Access
Page 1

Scroll to top